Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | Extending the myeloma arena beyond BCMA

Hermann Einsele • 12 Jun 2020
EHA 2020
Multiple Myeloma Antibodies CAR-T

Hermann Einsele, MD, FRCP, of the University of Würzburg, Würzburg, Germany, outlines studies investigating non-BCMA targets in multiple myeloma and their potential use in CAR-T cell therapy and bispecific antibodies. Such targets mentioned are GPRC5D, CD19, and SLAMF7. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Hermann Einsele

Improving CAR-T in myeloma: dual-targeting approaches and resistance to T-cell exhaustion
1:35
Improving CAR-T in myeloma: dual-targeting approaches and resistance to T-cell exhaustion
Hermann Einsele • 17 Sep 2025
Ongoing trials in CAR T-cell therapy for multiple myeloma: the CARTITUDE trials and aMMbition
3:17
Ongoing trials in CAR T-cell therapy for multiple myeloma: the CARTITUDE trials and aMMbition
Hermann Einsele • 17 Sep 2025
CAR-T in multiple myeloma: optimizing bridging therapy & moving CAR-T into earlier lines of therapy
11:27
CAR-T in multiple myeloma: optimizing bridging therapy & moving CAR-T into earlier lines of therapy
Hermann Einsele • 10 Feb 2025
Novel CAR-T constructs on the horizon for multiple myeloma
1:16
Novel CAR-T constructs on the horizon for multiple myeloma
Hermann Einsele • 10 Feb 2025

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Hermann Einsele • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Hermann Einsele • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Hermann Einsele • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Hermann Einsele • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals